Key Developments For Micrus Endovascular Corporation
Micrus Endovascular Corporation (MEND.O) (Consolidated Issue listed on NASDAQ Global Market)
Micrus Endovascular Corporation Raises FY 2010 Revenue Guidance
Micrus Endovascular Corporation announced that it has raised its expectations for total revenues for fiscal 2010 to be in the range of $84 million to $87 million. This compares with prior guidance for total revenues to be in the range of $82 million to $86 million. According to Reuters Estimates, analysts are expecting the Company to report revenue of $85 million for fiscal 2010.
Micrus Endovascular Corporation Signs Licensing And Development Agreement For Flow Diversion Technology
Micrus Endovascular Corporation and privately held Flexible Stenting Solutions Inc. of Eatontown, N.J. announced the signing of an exclusive agreement to jointly develop a flow diversion technology for neurovascular indications using both Micrus and Flexible Stenting Solutions technology, development capabilities and intellectual property. Micrus will be responsible for overseeing the regulatory and clinical process and will manufacture neurovascular products developed based on this collaborative agreement. Under the terms of the agreement, Micrus has made an upfront payment to Flexible Stenting Solutions and will make additional payments upon achieving certain development and regulatory milestones. Micrus will also pay a royalty on net sales of products incorporating the Flexible Stenting Solutions platform.
Micrus Endovascular Corporation Reaffirms FY 2010 Earnings Guidance; Raises FY 2010 Revenue Guidance
Micrus Endovascular Corporation raised its fiscal 2010 revenue guidance and expects total revenues to be in the range of $82 million to $86 million. The Company continues to expects to report profitability for fiscal 2010. According to Reuters Estimates, analysts are expecting the Company to report net profit of $0.73 million on revenue of $83 million for fiscal 2010.
Micrus Endovascular Corporation Announces Positive DeltaPaq Microcoil Study Results
Micrus Endovascular Corporation announced that study results presented recently at the 10th Congress of the World Federation of Interventional and Therapeutic Neuroradiology (WFITN) demonstrated that the DeltaPaq microcoil`s proprietary design appears to improve the uniformity of coil distribution within a cerebral aneurysm and the degree of microcoil packing in the aneurysm dome and neck, which may reduce the risk of aneurysm recurrence. The objective of this study was to assess whether the type of coil used had an impact on packing density and coil distribution within an aneurysm. This study suggests that the DeltaPaq microcoil may improve uniformity of coil distribution and demonstrated that DeltaPaq had a statistically significant greater packing density compared with traditional helical and complex coil designs. This is the first study to examine coil distribution in different sections of an aneurysm. Uniformity of distribution, which was found to be superior with DeltaPaq, is a possible predictor of treatment durabilit
Micrus Endovascular Corporation Issues FY 2010 Revenue Outlook In-Line With Analysts' Estimates; Comments on Profit Outlook
Micrus Endovascular Corporation announced that for fiscal 2010, it expects total revenues to be in the range of $80 million to $85 million. The Company expects to report profitability for fiscal 2010. According to Reuters Estimates, analysts are expecting the Company to report revenue of $85 million for fiscal 2010.
